Clinical Trial Update: Candesartan in the Prevention of Relapsing Atrial Fibrillation [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating candesartan for prevention of relapsing atrial fibrillation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Atacand (candesartan)

Snippet

Sponsor: Asker & Baerum Hospital | Conditions: Atrial Fibrillation | Phase 3 | Status: COMPLETED